Provided by Tiger Trade Technology Pte. Ltd.

Warren Buffett holdings

3,216.05
-29.3938-0.91%
Number of Gainers:9
Number of Losers:25
Number of Flat:1
PE:- -
High:3,244.52
Open:3,244.52
Low:3,209.42
Close:3,245.44
Volume:137.16M
Turnover:17.29B
Market Cap:11.45T
Float Cap:10.87T

Loading ...

US-Listed Shares of Teva Pharmaceutical up 3.5% Premarket After Co's Immune Disorder Drug Meets Main Goal in Mid-Stage Trial

THOMSON REUTERS
·
Sep 02

Novartis Signs Deal Worth up to $3.2 Billion for Alteogen's Drug Delivery Technology

Reuters
·
Sep 02

Teva's Stock Jumps over 3% as Immune Disorder Drug Meets Main Goal in Mid-Stage Trial

Reuters
·
Sep 02

BioAge Labs to Present at Citi Biopharma Back to School Conference Fireside Chat

Reuters
·
Sep 02

SpyGlass Pharma Management to Present at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 02

Alpha Tau CFO Levy to Join H.C. Wainwright Global Investor Conference Fireside Chat

Reuters
·
Sep 02

Kraft Heinz to Host Investor Day for Long-Term Strategy Update

Reuters
·
Sep 02

Teva Pharmaceutical Reports Positive Topline Data for Anti-IL-15 Drug in Celiac Disease

MT Newswires Live
·
Sep 02

Johnson & Johnson assumed with a Buy at UBS

TIPRANKS
·
Sep 02

Chevron, Keo Capital, Eni and Primavera Among Companies to Sign Energy Agreements in Venezuela Soon, Sources Say

THOMSON REUTERS
·
Sep 02

Liquefied Gas Shipper BW LPG Slides After $300 Mln Convertible Bond Offering

Reuters
·
Sep 02

Apple Grants Cook $47 Million Pay Package as He Transitions to Executive Chairman Role

Deep News
·
Sep 02

Amrize Falls; at Least Two Brokerages Downgrade Stock

Reuters
·
Sep 02

Chevron Outlines $7 Billion Plan to Expand in Venezuela

Dow Jones
·
Sep 02

New Apple Chief Makes Debut on Chinese Social Media Within Hours of Taking the Helm

Deep News
·
Sep 02

Protagonist Therapeutics CEO Patel Joins Fireside Chats at Two Investment Bank Conferences

Reuters
·
Sep 02

Teva: Tev '408 was Well-Tolerated with no Safety Signals Observed to Date

THOMSON REUTERS
·
Sep 02

Teva - Tev ‘408 Demonstrates Statistically Significant Prevention of Gluten-Induced Damage in Phase 2a Study

THOMSON REUTERS
·
Sep 02

Teva - Phase 2a Study Meets Primary Endpoint with Significant Prevention of Gluten-Induced Damage

THOMSON REUTERS
·
Sep 02

EyePoint to Join Citi, Cantor and Morgan Stanley Healthcare Investor Conferences

Reuters
·
Sep 02